Currently, CRISPR knock-ins in cancer cell lines are being developed with mutations in the various Cys residues (C65, C93, C99 and double-Cys mutations) in APE1/Ref-1 to further understand exactly how APE1/Ref-1 functions as a redox signaling molecule in cells [161]. The gene discussed is APEX1; the disease is cancer.